Abstract
Background:
Aquaporin-4 antibody–positive neuromyelitis optica spectrum disorder (AQP4-IgG NMOSD) requires lifelong immunosuppression to prevent relapses and disability. However, long-term treatment can increase the risk of severe and opportunistic infections, which can lead to hospitalisation and death.
Objectives:
To describe severe infections in AQP4-IgG NMOSD, their outcomes and risk factors, to inform safer long-term management.
Methods:
We retrospectively analysed prospectively collected data from 209 patients with AQP4-IgG NMOSD treated with immunosuppressive therapies and followed ⩾1 year at a UK national specialist service. Severe infections were defined as requiring intravenous therapy or hospitalisation. Predictors were identified using multivariate regression.
Results:
Forty-nine severe/opportunistic infections occurred in 37 patients (18%), accounting for one-third of deaths (10/30). Independent predictors were longer disease duration (OR 1.10, 95% CI 1.01–1.21), older age at onset (OR 1.04, 95% CI 1.00–1.08), comorbid autoimmune disease (OR 3.91, 95% CI 1.95–7.84) and diabetes mellitus (OR 7.48, 95% CI 2.24–24.98). Four patients died after their first infection. Among survivors, nine developed recurrent infections, six of whom died.
Conclusions:
Severe infections can be a complication of immunosuppression in NMOSD, especially in older patients and those with comorbidities. Risk stratification, comorbidity management and infection prevention should guide therapy to balance safety and relapse control.
Get full access to this article
View all access options for this article.
References
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
